Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.38 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1648596 | 0.80 | GAA (0.45) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2810520 | 0.76 | MAOB (0.40) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7242882 | 0.76 | MEN1 (0.61) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29408147 | 0.72 | GAA (0.54) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL123812 | 0.72 | GAA (0.54) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29144954 | 0.72 | GAA (0.54) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7238837 | 0.72 | SNCA (0.34) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3556450 | 0.71 | GAA (0.96) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12160120 | 0.71 | GAA (0.55) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29364653 | 0.71 | GAA (0.96) | GAAMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629997-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | Albireo AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| EP-4511038-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | Albireo AB (SE) | 2025-02-26 | — | — | EP | disclosed |
| US-12145959-B2 | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024184924-A1 | \"AN IMPROVED PROCESS FOR THE PREPARATION OF ODEVIXIBAT AND ITS CRYSTALLINE FORMS\ | RK PHARMA INC (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024121434-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | ALBIREO AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023203248-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | ALBIREO AB (SE) | 2023-10-26 | — | — | WO | disclosed |
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| CN-114096268-A | Methods for increasing growth in pediatric subjects with cholestatic liver disease | 米鲁姆制药公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114072153-A | Methods for treating cholestasis | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-2771003-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2006137796-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIC CONDITIONS | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1675820-A2 | PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1539120-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004113270-A2 | PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004006899-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| US-6624157-B2 | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | DING CHARLES Z (US) | 2001-11-08 | — | — | US | disclosed |
| EP-0918771-A4 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0918771-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998002436-A1 | THIADIOXOBENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | GAA 259/4885MEN1 3173/4885KMT2A 2618/4885 |
| US-12145959-B2 | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease | SLC10A1, SLC10A2, ABCB11 | GAA 259/4885MEN1 3173/4885KMT2A 2618/4885 |
| US-20010039273-A1 | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase | CBR1, CBR3, FNTB | GAA 4577/4885MEN1 4461/4885KMT2A 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.